|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| *Enter title in bold, normal size font without a reference number* | | | | |
| Design | *Objective terms describing the type of study (randomized, uncontrolled, retrospective, placebo-controlled, cross-over****, etc.);*** *N= (total subjects)* | | | |
| Objective | *State the objective (purpose) of the study using the author’s language* | | | |
| Study Groups | *Only the separate groups and their cohort number (n) should be listed. You can describe more details of the cohorts in the methods section so this section can stay very succinct.* | | | |
| Methods | *Include relevant inclusion/exclusion criteria (not a comprehensive list), data collection, clinical statistics, and any other information needed to understand the results. Any loose ends from all other sections are tied up here, as concisely as possible.* | | | |
| Duration | *Include the duration of the trial as a whole, as well as the duration of the interventions.* | | | |
| Outcome Measures | *If the primary outcome measure isn’t explicit from the study, all outcome measures applicable to the inquiry can be listed in this section. If the primary outcome measure is explicit, then make separate sections for ‘Primary’ and ‘Secondary’ Outcome Measures.*  *All outcome measures listed should correlate directly/exactly with the results presented later.* | | | |
| Baseline Characteristics |  | A | B | Placebo |
| Age, years |  |  |  |
| Women |  |  |  |
| White |  |  |  |
| --- |  |  |  |
| *Include relevant baseline characteristics* that will provide a general (big picture) view of the patients in the study. | | | |
| Results | Endpoint | A | B | Placebo |
| ---- |  |  |  |
| p-value vs placebo | p< | p< |  |
| *All results listed should correlate directly/exactly with the outcome measures presented previously.* *Results that do not have to do with the inquiry should not be included; just the stated outcomes need corresponding results.*  *Tables are encouraged to display the most info using the least space/words.* | | | |
| Adverse Events | Common Adverse Events: *(*or those deemed frequent; *if not listed in study, use N/A or “Not disclosed”)* | | | |
| Serious Adverse Events: *(or those deemed high risk; if not listed in study, use N/A or “Not disclosed”)* | | | |
| Percentage that Discontinued due to Adverse Events: *(if not listed in study, use N/A or “Not disclosed”)* | | | |
| Study Author Conclusions | *Include author’s conclusions on the question at hand, using full sentences. Don’t include any conclusions that don’t correspond to results we list.* | | | |
| InpharmD Researcher  Critique | *As the expert, add 1-2 sentences on strengths, weaknesses, and takeaways from this study.* | | | |